%0 Journal Article
%@ 2409-515X
%A  Xue Andrea
%A  Lénárt István
%A  Kincs Judit
%A  Szabó Hajnalka
%A  Párniczky Andrea
%A  Balogh István
%A  Deák Anna
%A  Monostori Péter
%A  Hegedűs Krisztina
%A  Szabó Attila
%A  Szatmári Ildikó
%A Klinikai Genetikai Tanszék DE / ÁOK / LMI KGT [2021-],
%A Gyermekgyógyászati Klinika SE / AOK / K GYGYK [2023-],
%A Gyermekgyógyászati Klinika és Gyermek Egészségügyi Központ SZTE / SZAOK GYKGYEK [2005-],
%D 2023
%F publicatio:35772
%J INTERNATIONAL JOURNAL OF NEONATAL SCREENING
%N 3
%T Neonatal Screening for Cystic Fibrosis in Hungary—First-Year Experiences
%U http://publicatio.bibl.u-szeged.hu/35772/
%V 9
%X The aim of this study is to evaluate the strategy of the cystic fibrosis newborn screening (CFNBS) programme in Hungary based on the results of the first year of screening. A combined immunoreactive trypsinogen (IRT) and pancreatitis-associated protein (PAP) CFNBS protocol (IRT/IRT×PAP/IRT) was applied with an IRT-dependent safety net (SN). Out of 88,400 newborns, 256 were tested screen-positive. Fourteen cystic fibrosis (CF) and two cystic fibrosis-positive inconclusive diagnosis (CFSPID) cases were confirmed from the screen-positive cases, and two false-negative cases were diagnosed later. Based on the obtained results, a sensitivity of 88% and a positive predictive value (PPV) of 5.9% were calculated. Following the recognition of false-negative cases, the calculation method of the age-dependent cut-off was changed. In purely biochemical CFNBS protocols, a small protocol change, even after a short period, can have a significant positive impact on the performance. CFNBS should be monitored continuously in order to fine-tune the screening strategy and define the best local practices.